Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1997 3
2000 1
2001 1
2002 2
2003 2
2004 2
2005 3
2006 2
2015 1
2016 2
2017 8
2018 7
2019 1
2020 1
2021 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection.
Salpini R, Battisti A, Piermatteo L, Carioti L, Anastasiou OE, Gill US, Di Carlo D, Colagrossi L, Duca L, Bertoli A, La Rosa KY, Fabeni L, Iuvara A, Malagnino V, Cerva C, Lichtner M, Mastroianni CM, De Sanctis GM, Paoloni M, Marignani M, Pasquazzi C, Iapadre N, Parruti G, Vecchiet J, Sarmati L, Andreoni M, Angelico M, Grelli S, T Kennedy P, Verheyen J, Aquaro S, Silberstein FC, Perno CF, Svicher V. Salpini R, et al. Among authors: pasquazzi c. Emerg Microbes Infect. 2020 Dec;9(1):928-939. doi: 10.1080/22221751.2020.1757998. Emerg Microbes Infect. 2020. PMID: 32312174 Free PMC article.
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.
Howe AYM, Rodrigo C, Cunningham EB, Douglas MW, Dietz J, Grebely J, Popping S, Sfalcin JA, Parczewski M, Sarrazin C, de Salazar A, Fuentes A, Sayan M, Quer J, Kjellin M, Kileng H, Mor O, Lennerstrand J, Fourati S, Di Maio VC, Chulanov V, Pawlotsky JM, Harrigan PR, Ceccherini-Silberstein F, Garcia F; SHARED Collaborators. Howe AYM, et al. JHEP Rep. 2022 Feb 24;4(5):100462. doi: 10.1016/j.jhepr.2022.100462. eCollection 2022 May. JHEP Rep. 2022. PMID: 35434589 Free PMC article.
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies.
Piermatteo L, D'Anna S, Bertoli A, Bellocchi M, Carioti L, Fabeni L, Alkhatib M, Frazia S, Lichtner M, Mastroianni C, Sanctis G, Marignani M, Pasquazzi C, Iapadre N, Parruti G, Cappiello G, Vecchiet J, Malagnino V, Grelli S, Ceccherini-Silbertein F, Andreoni M, Sarmati L, Svicher V, Salpini R. Piermatteo L, et al. Among authors: pasquazzi c. Emerg Microbes Infect. 2023 Dec;12(1):2219347. doi: 10.1080/22221751.2023.2219347. Emerg Microbes Infect. 2023. PMID: 37288750 Free PMC article.
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxì A, Andreoni M, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network Group (Vironet C). Di Maio VC, et al. Among authors: pasquazzi c. Liver Int. 2021 Aug;41(8):1802-1814. doi: 10.1111/liv.14797. Epub 2021 Feb 8. Liver Int. 2021. PMID: 33497016
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.
Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Bertoli A, et al. Among authors: pasquazzi c. Sci Rep. 2018 Jun 12;8(1):8988. doi: 10.1038/s41598-018-26862-y. Sci Rep. 2018. PMID: 29895871 Free PMC article. Clinical Trial.
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. Petta S, et al. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28497758
Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study.
Lanini S, Scognamiglio P, Mecozzi A, Lombardozzi L, Vullo V, Angelico M, Gasbarrini A, Taliani G, Attili AF, Perno CF, De Santis A, Puro V, Cerqua F, D'Offizi G, Pellicelli A, Armignacco O, Mennini FS, Siciliano M, Girardi E, Panella V, Ippolito G; members of the Lazio Region HCV treatment group. Lanini S, et al. BMC Infect Dis. 2018 May 16;18(1):223. doi: 10.1186/s12879-018-3125-6. BMC Infect Dis. 2018. PMID: 29769038 Free PMC article.
38 results